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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the beneficial and harmful effects of banding ligation versus no intervention in adults with cirrhosis and gastro-oesophageal
varices that have not bled.
B A C K G R O U N D
Description of the condition
Oesophageal varices develop as a result of portal hypertension
(Bosch 2003; Triantos 2007). At the time of diagnosis, approx-
imately 30% of people with cirrhosis have oesophageal varices
(D’Amico 1995; D’Amico 1999; D’Amico 2007; De Lisi 2010).
In people with cirrhosis who do not have varices at the time of
diagnosis, the incidence of oesophageal varices is 5% at one year
and 28% at three years (Merli 2003). The factors precipitating
variceal haemorrhage are still not clear. The risk of bleeding is in-
creased when the size of the varices is more than five mm. The risk
of bleeding also increases with the severity of liver disease. In peo-
ple with alcohol-related cirrhosis, the risk of bleeding depends on
whether or not they continue to drink. Once varices are present,
they tend to enlarge. Of people with small varices at the outset,
12% will have large varices at one year and 31% at three years
(Merli 2003), resulting in a higher risk of bleeding. The estimated
two-year incidence of bleeding is approximately 24% (D’Amico
1995; D’Amico 1999) and most episodes of bleeding from varices
(70%) occur within two years of diagnosis. Although the in-hos-
pital mortality associated with variceal bleeding has decreased in
recent years due to improvements in endoscopic therapy and the
use of antibiotic prophylaxis, the reported mortality rate still lies
between 12% to 44%. The risk of death within six weeks of the
initial variceal haemorrhage is below 10% in Child-Pugh Class A
and greater than 32% in those in Child-Pugh Class C (Carbonell
2004).
Description of the intervention
As approximately 30% of people with cirrhosis with oesophageal
varices develop bleeding and 12% to 44% die as a result of the
first bleed, prophylactic regimens to prevent bleeding are impor-
tant (Garcia-Tsao 2007; Garcia-Tsao 2008). Nonselective beta-
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blocker therapy reduces azygos blood flow and variceal pressure
and is used for the primary prophylaxis of variceal haemorrhage
(D’Amico 1999; D’Amico 2007). About one in three patients
do not respond to beta-blockers or develop adverse events, lead-
ing to a reduction in dose or treatment withdrawal (Gluud 2007;
Gonzalez 2008). Randomised clinical trials (RCTs) have been used
to assess endoscopic interventions as an alternative option (van
Buuren 2003;Gluud 2007; Tripathi 2007). Variceal sclerotherapy,
which involves injecting a strong and irritating sclerosant or glue,
is associated with serious adverse events including severe bleeding
and oesophageal strictures (Schmitz 2001). Banding ligation may
provide a safer option (Gluud 2007).
How the intervention might work
Banding devices use a means of capturing the target tissue while
a small-diameter circular band is deployed around the base of
the tissue (ASGE 2008). The band may be rubber, latex, or a
similar material. The ligation procedure results in tight compres-
sion with vascular compromise leading to thrombosis, necrosis,
and sloughing. Previous banding devices used an overtube for the
repeated intubation, allowing the placement of multiple bands
(Collins 2001). The insertion of an overtube was associated with
adverse events including perforation of the oesophagus (Wong
2000; Gluud 2007; Gluud 2012). At present, multi-band devices
(without an overtube) are used, resulting in considerably fewer
adverse events (ASGE 2008).
Why it is important to do this review
The effect of banding ligation for preventing variceal bleeding is a
clinically-important question. Endoscopic variceal ligation is ad-
vocated as an alternative option for primary prophylaxis (Imperiale
1992; Gluud 2007). Although banding ligation is a relatively sim-
ple endoscopic procedure, repeated banding is normally required
to achieve eradication of varices and for surveillance for variceal
recurrence. A systematic review found that banding ligation may
be superior to beta-blockers in the prevention of bleeding (Gluud
2007). The review did not include RCTs with a no intervention
control. Several RCTs have compared banding ligation versus no
intervention (Sarin 1996; Lay 1997; Lo 1999; Svoboda 1999;
Triantos 2005). Conducting a systematic review with meta-anal-
yses of these trials may provide important information about the
beneficial and harmful effects of banding ligation.
O B J E C T I V E S
To assess the beneficial and harmful effects of banding ligation ver-
sus no intervention in adults with cirrhosis and gastro-oesophageal
varices that have not bled.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials (RCTs) irrespective of publication type,
publication status, and language. If, during the selection of trials,
we identify observational studies (i.e. quasi-randomised studies;
cohort studies; or patient reports) reporting adverse events, we will
include these studies for a review of the adverse events. We will
not specifically search for observational studies for inclusion in
this review, which is a known limitation of our systematic review.
Types of participants
We will include people with cirrhosis and endoscopically verified
gastro-oesophageal varices that have not bled (primary preven-
tion), irrespective of the size of the varices or the hepatic venous
pressure gradient.
Types of interventions
Banding ligation versus no intervention. Considering the nature
of the intervention, we do not believe that sham interventions are
ethical as they may have associated morbidity and no benefit to
the participant. In addition, we do not believe it is possible to
adequately double blind banding ligation. If we do identify RCTs
using blinding based on sham banding ligation, we will consider
including them.Wewill not compare banding ligation versus non-
selective beta-blockers due to overlap with another review (Gluud
2012), but wewill include RCTs inwhich participants received the
same supportive treatment in the intervention and control group.
Types of outcome measures
We will assess all outcomes at the maximum duration of follow-
up.
Primary outcomes
• All-cause mortality.
• Serious adverse events, defined as any untoward medical
occurrence that does not necessarily have a causal relationship
with the treatment (ICH-GCP 1997). We will define serious
adverse events as those that led to death, were life threatening, or
required hospitalisation or prolongation of hospitalisation
(ICH-GCP 1997). We will analyse adverse events as a composite
outcome (CHBG 2017).
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Secondary outcomes
• Upper gastrointestinal bleeding.
• Variceal bleeding.
• Quality-of-life.
• Bleeding-related mortality.
• Non-serious adverse events (all adverse events, which do
not fulfil the criteria for serious adverse events as defined above).
Search methods for identification of studies
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register (CHBG 2017), Cochrane Central Register of Con-
trolledTrials (CENTRAL) (Cochrane Library),MEDLINE (Ovid
SP), Embase (Ovid SP), and Science Citation Index Expanded
(Web of Science) using the strategies with the expected time spans
described in Appendix 1. We also plan to search LILACS, Rus-
sian, Chinese and Japanese databases with help from theCochrane
Hepato-Biliary Group.
Searching other resources
We will scan the reference lists of relevant articles and proceed-
ings from meetings of the British Society for Gastroenterology
(BSG), the British Association for the Study of the Liver (BASL),
the European Association for the Study of the Liver (EASL), the
United European Gastroenterology Week (UEGW), the Ameri-
can Gastroenterological Association (AGA), and the American As-
sociation for the Study of Liver Diseases (AASLD). We will write
to the principal authors of RCTs and the device companies for
additional information about completed RCTs and for informa-
tion about any ongoing RCTs. We will also search online trial
registries such as ClinicalTrials.gov (clinicaltrials.gov/), European
Medicines Agency (EMA) (www.ema.europa.eu/ema/),WHO In-
ternational Clinical Trial Registry Platform (www.who.int/ictrp),
and the Food and Drug Administration (FDA) (www.fda.gov)
for ongoing or unpublished trials. In addition, we plan to search
Google Scholar using the terms (band* OR ligat*) AND bleed*
AND varic* AND cirrhosis.
Data collection and analysis
Two review authors (CWY and SV) will read the electronic
searches, perform additional manual searches, and list potentially
eligible RCTs, read the potentially eligible trial reports, and par-
ticipate in the final selection of those to be included in the analy-
ses. We will reach the final selection through consensus. For RCTs
reported in more than one publication, we will select the paper
reporting the longest duration of follow-up as the primary refer-
ence.
Selection of studies
CWY and SV will participate in the searches for eligible trials
and data extraction, and list excluded trials with the reason for
exclusion. We will all participate in the final selection of trials and
resolve disagreements will through discussion before the analyses.
Data extraction and management
Two review authors (CWY and SV)will independently collect data
and resolve contrary opinions through discussion.MYMwill act as
ombudsman in case disagreements cannot be resolved through dis-
cussion. The collected data will include information on: i) RCTs:
design (cross-over or parallel), settings (number of clinical sites;
inclusion period), country of origin; ii) participants: size of varices;
proportion of participants with high risk varices (based on the pri-
mary authors’ definition), mean age, proportion of men, aetiology
of cirrhosis, proportion with Child-Pugh A/B/C, and iii) inter-
ventions: number of banding sessions, number of bands used per
session.
Wewill gather the primary and secondary outcome data, including
the criteria used in the definition of high and low risk varices,
methods and definitions used to assess bleeding, and bias control.
If we cannot find the relevant data in the published trial reports,
we will write to the primary investigators to ask for additional
information.
Assessment of risk of bias in included studies
We will assess bias control using the domains described in the
Cochrane Hepato-Biliary (CHB) Module (CHBG 2017), classify
the risk of bias for separate domains as high, unclear, or low, and
the overall assessment as high or low risk of bias.
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random.
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Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We will
only include such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: blinding of participants and personnel
performed adequately using a placebo. We defined lack of
blinding as not likely to affect the evaluation of mortality
(Hrobjartsson 2001; Savovic 2012; Savovic 2012a).
• Unclear risk of bias: insufficient information to assess
blinding.
• High risk of bias: no blinding or incomplete blinding.
Blinding of outcome assessors
• Low risk of bias: blinding of outcome assessors performed
adequately using a placebo. We defined lack of blinding as not
likely to affect the evaluation of mortality (Hrobjartsson 2001;
Savovic 2012; Savovic 2012a).
• Unclear risk of bias: there was insufficient information to
blinding.
• High risk of bias: no blinding or incomplete blinding.
Incomplete outcome data
• Low risk of bias: missing data unlikely to make treatment
effects depart from plausible values. The investigators used
sufficient methods, such as intention-to-treat analyses with
multiple imputations or carry-forward analyses to handle missing
data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported clinically-relevant
outcomes (mortality, hepatic encephalopathy, and serious adverse
events). If we have access to the original trial protocol, the
outcomes selected should be those called for in that protocol. If
we obtain information from a trial registry (such as
www.clinicaltrials.gov), we will consider that information reliable
only if the investigators registered the trial before inclusion of the
first participant.
• Unclear risk of bias: not all predefined outcomes were
reported fully, or it was unclear whether data on these outcomes
were recorded or not.
• High risk of bias: one or more predefined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias as the trial does not provide any information on
clinical trial support or sponsorship.
• High risk of bias: the trial is sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
factors that could put it at risk of bias (e.g. medicinal dosing
problems or follow-up (as defined below).
• Unclear risk of bias: the trial may or may not have been free
of other factors that could put it at risk of bias
• High risk of bias: there were other factors in the trial that
could put it at risk of bias such as the administration of
inappropriate treatments being given to the controls (e.g. an
inappropriate dose) or follow-up (e.g. the trial included different
follow-up schedules for participants in the allocation groups).
Overall bias assessment
• Low risk of bias: if trials are assessed as ’low risk of bias’ in
all bias risk domains
• High risk of bias: if trials are assessed as having an ’unclear
risk of bias’ or a ’high risk of bias’ in one or more of the bias risk
domains.
Measures of treatment effect
We will use risk ratios (RR) for dichotomous outcomes and mean
differences (MD) for continuous outcomes, both with 95% con-
fidence intervals (CI). For statistically significant outcomes (based
on the 95% CI), we will calculate the number needed to treat
for an additional beneficial outcome (NNTB) as 1/ risk difference
(RD).
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Unit of analysis issues
We do not expect to identify cross-over RCTs, but if we do, we
will include the first trial period in our analyses.
Dealing with missing data
We will extract data on all randomised participants in order to
allow intention-to-treat analyses. To evaluate the importance of
missing data, we will conduct a worst-case scenario analysis with
inclusion of missing outcomes as treatment failures. In addition,
we will conduct ’extreme’ best-case and worst-case scenario analy-
ses in which we include missing outcome data as treatment failures
in the intervention group and successes in the control group and
vice versa.
Assessment of heterogeneity
We will evaluate heterogeneity through visual inspection of forest
plots and express heterogeneity as I2 values using the following
thresholds: 0% to 40% (unimportant), 40% to 60% (moderate),
60% to 80% (substantial), and > 80% (considerable). We will
include this information in the ’Summary of findings’ tables (
GRADEpro).
Assessment of reporting biases
For meta-analyses with at least 10 RCTs, we will assess reporting
biases through regression analyses and funnel plots.
Data synthesis
We will perform the analyses in Review Manager 5 (RevMan
2014), STATA (Stata 14), and Trial Sequential Analysis (TSA
2011).
Meta-analysis
We will undertake random-effects and fixed-effect meta-analyses.
If the estimates of the random-effects and fixed-effect meta-anal-
yses are similar, then we will assume that any small-study effects
have little effect on the intervention effect estimate. If the random-
effects estimate is more beneficial, we will re-evaluate whether it is
reasonable to conclude that the intervention was more effective in
the smaller studies. If the larger studies tend to be those conducted
with more methodological rigour, or conducted in circumstances
more typical of the use of the intervention in practice, thenwe will
report the results of meta-analyses restricted to the larger, more
rigorous studies. Based on the expected clinical heterogeneity, we
expect that a number of analyses will display statistical between
trial heterogeneity (I² > 0%). For random-effect models, preci-
sion will decrease with increasing heterogeneity and confidence
intervals will widen correspondingly. We therefore expect that the
random-effects model will give the most conservative (and a more
correct) estimate of the intervention effect. We will base our main
conclusions on the model that provides the most conservative es-
timate.
Trial Sequential Analysis
We will perform Trial Sequential Analysis (TSA 2011) in order
to evaluate whether apparently significant beneficial and harm-
ful intervention effects could be caused by random error (‘play of
chance’).We will define the required information size (also known
as the ’diversity-adjusted required information size’) as the number
of participants needed to detect or reject an intervention effect
based on the relative risk reduction (RRR) and control group risk
(CGR). The analyses show firm evidence if the Z-curve crosses the
monitoring boundary (also known as the ’trial sequential moni-
toring boundary ’) before reaching the required information size.
We will set the relative risk reduction (RRR) to the highest up-
per confidence interval and use the control group proportion ob-
served in the meta-analysis, set alpha to 3.3% (primary outcomes)
or 1.66% (secondary outcomes), power to 90%, and use model-
based diversity.
Subgroup analysis and investigation of heterogeneity
We will conduct subgroup analyses to evaluate the effect of band-
ing:
• trials assessed as having a low risk compared to a high risk
of bias;
• people with high risk varices compared to people with low
risk varices;
• participants who achieve obliteration of varices compared
to those who do not.
Sensitivity analysis
Wewill conduct a worst-case scenario analysis and extreme-worst-
case and best-case scenario analyses as described above.
’Summary of findings’ tables
We will use the GRADE system (GradePro 2008) to evaluate the
quality of the evidence for the outcomes reported in the review
considering the within-study risk of bias (methodological qual-
ity), indirectness of evidence, heterogeneity, imprecision of effect
estimate, and risk of publication bias.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search terms
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date will be given at review stage. (beta-blocker* OR ’adrenergic beta antagonist*’
OR propranolol OR atenolol OR nadolol OR
metoprolol OR bisoprolol OR carvedilol OR ter-
tatolol OR nipradilol OR penbutolol OR timolol
OR mepindolol) AND ’*esophageal varic*’
Cochrane Central Register of Controlled
Trials (CENTRAL) (Cochrane Library)
Latest issue. #1 MeSH descriptor Adrenergic beta-Antagonists
explode all trees 8964
#2 MeSH descriptor Propranolol explode all trees
2458
#3 MeSH descriptor Atenolol explode all trees
1626
#4 MeSH descriptor Nadololexplode all trees 161
#5 MeSH descriptor Metoprololexplode all trees
1308
#6 MeSH descriptor Bisoprololexplode all trees
234
#7MeSH descriptor Penbutololexplode all trees 51
#8 MeSH descriptor Timololexplode all trees 851
#9 beta-blocker* OR ’adrenergic beta antagonist*’
OR propranolol OR atenolol OR nadolol OR
metoprolol OR bisoprolol OR carvedilol OR ter-
tatolol OR nipradilol OR penbutolol OR timolol
OR mepindolol 12373
#10 (#1 OR #2 OR ( #3 AND O#4 AND OR#5
) OR #6 OR #7 OR #8 OR #9) 14182
#11 MeSH descriptor Esophageal and Gastric
Varices explode all trees 740
#12 *esophageal varic* 1269
#13 (#11 OR #12) 1269
#14 (#10 AND #13) 284
MEDLINE (Ovid SP) 1946 to the date of search. 1. exp Adrenergic beta-Antagonists/
2. exp Propranolol/
3. exp Atenolol/
4. exp Nadolol/
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(Continued)
5. exp Metoprolol/
6. exp Bisoprolol/
7. exp Penbutolol/
8. exp Timolol/
9. (beta-blocker* or adrenergic beta antagonist* or
propranolol or atenolol or nadolol or metoprolol or
bisoprolol or carvedilol or tertatolol or nipradilol or
penbutolol or timolol or mepindolol).mp. [mp=ti-
tle, original title, abstract, name of substance word,
subject heading word, unique identifier]
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. exp “Esophageal and Gastric Varices”/
12. ((oesophageal or esophageal) and varic*).mp.
[mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
13. 11 or 12
14. 10 and 13
15. (random* or blind* or placebo* or meta-anal-
ysis).mp. [mp=title, original title, abstract, name
of substance word, subject heading word, unique
identifier]
16. 14 and 15
Embase (Ovid SP) 1974 to the date of search. 1. exp beta adrenergic receptor blocking agent/
2. exp PROPRANOLOL/
3. exp ATENOLOL/
4. exp NADOLOL/
5. exp METOPROLOL/
6. exp BISOPROLOL/
7. exp CARVEDILOL/
8. exp TERTATOLOL/
9. exp NIPRADILOL/
10. exp PENBUTOLOL/
11. exp TIMOLOL/
12. exp MEPINDOLOL/
13. (beta-blocker* or adrenergic beta antagonist*
or propranolol or atenolol or nadolol or meto-
prolol or bisoprolol or carvedilol or tertatolol or
nipradilol or penbutolol or timolol or mepindolol)
.mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device man-
ufacturer, drug manufacturer]
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
or 11 or 12 or 13
15. exp esophagus varices/
16. ((oesophageal or esophageal) and varic*).
mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device man-
ufacturer, drug manufacturer]
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(Continued)
17. 15 or 16
18. 14 and 17
19. (random* or blind* or placebo* or meta-analy-
sis).mp. [mp=title, abstract, subject headings, head-
ing word, drug trade name, original title, device
manufacturer, drug manufacturer]
20. 18 and 19
Science Citation Index Expanded (Web of
Science)
1900 to the date of search. #4 #3 AND #2 AND #1
#3 TS=(random* or blind* or placebo* or meta-
analysis)
#2 TS=((oesophageal or esophageal) and varic*)
#1 TS=(beta-blocker* or adrenergic beta antago-
nist* or propranolol or atenolol or nadolol or meto-
prolol or bisoprolol or carvedilol or tertatolol or
nipradilol or penbutolol or timolol or mepindolol)
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